Comparing Long-Term Survival Outcomes for Muscle-Invasive Bladder Cancer Patients Who Underwent with Radical Cystectomy and Bladder-Sparing Trimodality Therapy: A Multicentre Cohort Analysis
Table 1
Characteristics of RC-MIBC cohort versus TMT-MIBC cohort after propensity score matching.
Characteristics
RC-MIBC cohort
TMT-MIBC cohort
value
No.
%
No.
%
All
891
100.0
891
100.0
Demographic and clinicopathological characteristics
Age at MIBC diagnosis
60-69
494
55.4
477
53.5
0.654
0.419
70-79
397
44.6
414
46.5
Median age (years)
68
69
Gender
Men
635
71.3
625
70.2
0.271
0.603
Women
256
28.7
266
29.8
Year at diagnosis
2005-2009
383
43.0
381
42.8
0.009
0.924
2010-2014
508
57.0
510
57.2
Highest education achievement
Elementary school
396
44.5
411
46.1
2.082
0.353
Secondary school
372
41.7
377
42.3
University and above
123
13.8
103
11.6
Clinical T stage
T2
585
65.7
597
66.4
3.936
0.269
T3a
195
21.9
202
22.7
T3b
58
6.5
57
6.4
T4a
53
5.9
35
4.5
Charlson Comorbidity Index (CCI)
0
548
61.5
541
60.7
0.376
0.829
1
185
20.8
182
20.4
2 or more
158
17.7
168
18.9
Treatment information
Neoadjuvant chemotherapy, (%)
Yes
153
17.2
36
4.0
81.022
<0.001
No
738
82.8
855
96.0
Adjuvant chemotherapy, (%)
Yes
296
33.2
515
57.9
108.532
<0.001
No
595
66.8
376
42.2
Radiation dose, (%)
<60 Gy
782
87.8
467
52.4
265.607
<0.001
≥60 Gy
109
12.2
424
47.6
Response to chemoradiation, (%)
Complete
613
68.8
642
72.1
2.267
0.132
Incomplete
278
31.2
249
27.9
The propensity score was constructed for each participant according to the following covariates: age, gender, year at diagnosis, education achievement, clinical T stage, and Charlson Comorbidity Index (CCI). RC: radical cystectomy; TMT: bladder-sparing trimodality therapy; MIBC: muscle-invasive bladder cancer.
